|
|
Line 191: |
Line 191: |
| </div>}} | | </div>}} |
| {{familytree/end}} | | {{familytree/end}} |
|
| |
| ==Therapeutic Approach==
| |
| Shown below an algorithm depicting the general therapeutic approaches of [[infective endocarditis]] based on the 2005 [[American Heart Association]] (AHA) technical review and medical position statement regarding guidelines on [[infective endocarditis]].<ref name="Baddour-2005">{{Cite journal | last1 = Baddour | first1 = LM. | last2 = Wilson | first2 = WR. | last3 = Bayer | first3 = AS. | last4 = Fowler | first4 = VG. | last5 = Bolger | first5 = AF. | last6 = Levison | first6 = ME. | last7 = Ferrieri | first7 = P. | last8 = Gerber | first8 = MA. | last9 = Tani | first9 = LY. | title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = e394-434 | month = Jun | year = 2005 | doi = 10.1161/CIRCULATIONAHA.105.165564 | PMID = 15956145 }}</ref>
| |
|
| |
| {{Familytree/start}}
| |
|
| |
| {{Familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | |C01= '''❑ Evaluate the patient'''}}
| |
| {{Familytree | | | | | | | | | | |!| | | | | | | | | | | | | |}}
| |
| {{Familytree | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | |}}
| |
| {{Familytree | | | | D01 | | | | | | | | | | D02 | | | | | | | |D01= ❑ '''Acute presentation or hemodynamically unstable'''|D02= ❑ '''Subacute presentation and hemodynamically stable''' }}
| |
| {{Familytree | | | | |!| | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | E01 | | | | | | | | | | E02 | | | | | | |E01= ❑ Stabilize the patient|E02= ❑ Wait for blood culture results}}
| |
| {{Familytree | | | | |!| | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | F01 | | | | | | | | | | F02 | | | | | | | | F01=❑ Don`t wait for blood culture results and start [[Endocarditis antimicrobial treatment#Empirical Antibiotic Therapy|empirical antibiotic therapy]]|F02=Start antibiotic therapy according to the detected pathogen}}
| |
| {{Familytree | | | | | | | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | |,|-|-|-|-|-|v|-|-|-|-|-|+|-|-|-|-|-|v|-|-|-|-|-|.| |}}
| |
| {{Familytree | | | | |!| | | | | |!| | | | | |!| | | | | |!| | | | | |!| | |}}
| |
| {{Familytree | | | | G01 | | | | G02 | | | | G03 | | | | G04 | | | | G05 | |G01= [[Endocarditis antimicrobial treatment#Streptococci|Streptococci antibiotic regimen]] |G02= [[Endocarditis antimicrobial treatment#Enterococci|Enterococci antibiotic regimen]]|G03= [[Endocarditis antimicrobial treatment#Staphylococci|Staphylococci antibiotic regimen]]|G04=[[Endocarditis antimicrobial treatment#HACEK Organisms|HACEK Organisms antibiotic regimen]]|G05= [[Endocarditis antimicrobial treatment#Culture Negative Endocarditis|Culture negative antibiotic regimen]]}}
| |
| {{Familytree/end}}
| |
|
| |
|
| |
| === Therapeutic Approach===
| |
| Shown below an algorithm depicting the general therapeutic approaches of [[infective endocarditis]] based on the 2005 [[American Heart Association]] (AHA) technical review and medical position statement regarding guidelines on [[infective endocarditis]].<ref name="Baddour-2005">{{Cite journal | last1 = Baddour | first1 = LM. | last2 = Wilson | first2 = WR. | last3 = Bayer | first3 = AS. | last4 = Fowler | first4 = VG. | last5 = Bolger | first5 = AF. | last6 = Levison | first6 = ME. | last7 = Ferrieri | first7 = P. | last8 = Gerber | first8 = MA. | last9 = Tani | first9 = LY. | title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = e394-434 | month = Jun | year = 2005 | doi = 10.1161/CIRCULATIONAHA.105.165564 | PMID = 15956145 }}</ref>
| |
|
| |
| {{Familytree/start}}
| |
|
| |
| {{Familytree | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | |C01= '''❑ Evaluate the patient'''}}
| |
| {{Familytree | | | | | | | | | | |!| | | | | | | | | | | | | |}}
| |
| {{Familytree | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | |}}
| |
| {{Familytree | | | | D01 | | | | | | | | | | D02 | | | | | | | |D01= ❑ '''Acute presentation or hemodynamically unstable'''|D02= ❑ '''Subacute presentation and hemodynamically stable''' }}
| |
| {{Familytree | | | | |!| | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | E01 | | | | | | | | | | E02 | | | | | | |E01= ❑ Stabilize the patient|E02= ❑ Wait for blood culture results}}
| |
| {{Familytree | | | | |!| | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | F01 | | | | | | | | | | F02 | | | | | | | | F01=❑ Don`t wait for blood culture results and start [[Endocarditis antimicrobial treatment#Empirical Antibiotic Therapy|empirical antibiotic therapy]]|F02=Start antibiotic therapy according to the detected pathogen}}
| |
| {{Familytree | | | | | | | | | | | | | | | | |!| | | | | | | |}}
| |
| {{Familytree | | | | |,|-|-|-|-|-|v|-|-|-|-|-|+|-|-|-|-|-|v|-|-|-|-|-|.| |}}
| |
| {{Familytree | | | | |!| | | | | |!| | | | | |!| | | | | |!| | | | | |!| | |}}
| |
| {{Familytree | | | | G01 | | | | G02 | | | | G03 | | | | G04 | | | | G05 | |G01= [[Endocarditis antimicrobial treatment#Streptococci|Streptococci antibiotic regimen]] |G02= [[Endocarditis antimicrobial treatment#Enterococci|Enterococci antibiotic regimen]]|G03= [[Endocarditis antimicrobial treatment#Staphylococci|Staphylococci antibiotic regimen]]|G04=[[Endocarditis antimicrobial treatment#HACEK Organisms|HACEK Organisms antibiotic regimen]]|G05= [[Endocarditis antimicrobial treatment#Culture Negative Endocarditis|Culture negative antibiotic regimen]]}}
| |
| {{Familytree/end}}
| |
|
| |
|
| ===Modified Duke Criteria=== | | ===Modified Duke Criteria=== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farman Khan, MD, MRCP [2]; Mohamed Moubarak, M.D. [3]
Definition
Infection of the endothelium of the heart including but not limited to the valves. It can be either acute or subacute. Acute bacterial endocarditis is defined as Infection of normal heart valves with a virulent organism like S. aureus, Group A or other beta-hemolytic streptococci, Streptococcus pneumoniae. Subacute bacterial endocarditis is an indolent infection of abnormal valves with less virulent organism like Streptococcus viridans.
Criteria |
Definite Infective Endocarditis According to Modified Duke Criteria
|
Pathological Criteria |
- Microorganisms demonstrated by culture or histological examination of a vegetation
- Pathological lesions; vegetation or intracardiac abscess confirmed by histological examination showing active endocarditis
|
Clinical Criteria |
- 2 major criteria; or
- 1 major criterion and 3 minor criteria; or
- 5 minor criteria
|
Possible IE |
- 1 major criterion and 1 minor criterion; or
- 3 minor criteria
|
Rejected |
- Firm alternative diagnosis explaining evidence of IE; or
- Resolution of IE syndrome with antibiotic therapy for 4 days; or
- No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days; or
- Does not meet criteria for possible IE as above
|
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Endocarditis can be a life-threatening condition if it is left untreated, and it must be treated as such irrespective of the causes.
Common Causes
Management
Diagnostic approach
Shown below is an algorithm summarizing the approach to infective endocarditis.
| | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | Does the patient have any of the following:
❑ Unexplained fever for more than 48 hours and high risk for infective endocarditis
- ❑ Congenital or acquired valvular heart disease
- ❑ Previous infective endocarditis
- ❑ Prosthetic heart valve
- ❑ Congenital heart malformation
- ❑ Immunodeficiency
- ❑ History of drug injection
❑ Newly diagnosed valve regurgitation
| | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | |
❑ Order a TTE
❑ Order a TEE if one or more of the following is present
- ❑ Non diagnostic TTE in a suspected infective endocarditis (Class I, level of evidence B)
- ❑ Clinical complications (Class I, level of evidence B)
- ❑ Intracardiac device leads (Class I, level of evidence B)
- ❑ Staphylococcus aureus bacteremia without a known cause (Class IIa, level of evidence B)
- ❑ Prosthetic valve with persistent fever without bacteremia (Class IIa, level of evidence B)
- ❑ Prosthetic valve with a new murmur (Class IIa, level of evidence B)
- ❑ Nosocomial Staphylococcus aureus bacteremia with known extra-cardiac port of entry (Class IIb, level of evidence B)
| | | | |
| | | | | | | | | | | | | | | |
| | | | | | | Evaluate the Modified Duke Criteria for infective endocarditis:
❑ Two major criteria, OR
❑ One major and three minor criteria, OR
❑ Five minor criteria | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | ❑ Consult an infectious disease specialist ❑ Consult a cardiologist ❑ Consult a cardiac surgeon | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | Reevaluate the patient with TTE and/or TEE
❑ Change in clinical signs and symptoms
- ❑ New murmur
- ❑ Embolism
- ❑ Persistent fever
- ❑ Heart failure
- ❑ Abscess
- ❑ Atrioventricular heart block
❑ High risk of complications
- ❑ Large vegetations on echocardiogram
- ❑ Staphylococcus, enterecoccal, or fungal infections
| | | | |
Modified Duke Criteria
Shown below is a table summarizing the major and minor Modified Duke Criteria.
Major criteria |
Minor criteria
|
1- Positive Blood Culture for Infective Endocarditis
❑ Typical microorganism consistent with infective endocarditis from 2 separate blood cultures, in the absence of a primary focus:
- ❑ Viridans streptococci, streptococcus bovis
- ❑ HACEK group
- ❑ Community-acquired staphylococcus aureus
- ❑Enterococci
OR
❑ Microorganisms consistent with infective endocarditis from persistently positive blood cultures defined as:
- ❑ At least 2 positive cultures of blood samples drawn >12 hours apart, or
- ❑ All of 3 or a majority of 4 separate cultures of blood (with first and last sample drawn 1 hour apart)
OR
❑ Single positive blood culture for Coxiella burnetii or anti–phase 1 IgG antibody titer >1:800|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left
2-Echocardiographic evidence of endocardial involvement
❑ Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation, or
❑ Abscess, or
❑ New partial dehiscence of prosthetic valve, or
❑ New valvular regurgitation
|
1- Predisposition
❑ Predisposing heart condition or intravenous drug use
2- Fever
❑ Temperature > 38.0° C (100.4° F)
3- Vascular phenomena
❑ Major arterial emboli
❑ Septic pulmonary infarcts
❑ Mycotic aneurysm
❑ Intracranial hemorrhage
❑ Conjunctival hemorrhage
❑ Janeway lesions
4- Immunologic phenomena
❑ Glomerulonephritis
❑ Osler's nodes
❑ Roth spots
❑ Rheumatoid factor
5- Microbiological evidence
❑ Positive blood culture but does not meet a major criterion as noted above
OR
❑ Serological evidence of active infection with organism consistent with infectious endocarditis
|
Prophylactic Approach
Shown below an algorithm depicting the general prophylactic approaches of infective endocarditis based on 2014 AHA/ACC Guideline for the management of patients with valvular heart disease.[2]
Do's
- Elicit a full medical history to help detecting the minor Duke criteria for the diagnosis.
- Initiate antibiotic therapy after withdrawing blood for culture (Class I, level of evidence B).[2]
- Do a TEE intraoperatively among patients scheduled for valve surgery for infective endocarditis (Class I, level of evidence B).[2]
- Consider ordering a cardiac CT scan when echocardiography does not provide clear details about the cardiac anatomy in the context of suspected paravalvular infections (Class IIa, level of evidence B).[2]
Dont's
- Don`t wait for blood culture results in acute cases, or hemodynamically unstable patients, and start empirical antibiotic therapy.
- Don't administer prophylaxis for infective endocarditis in patients with valvular heart disease who are at risk infective endocarditis for procedures such as TEE, cystoscopy, esophagogastroduodenoscopy or colonoscopy without any evidence of active infection (Class III; level of evidence B).[2]
References
Template:WikiDoc Sources